Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 AlteredExpression group BEFREE 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exacerbates mitochondrial impairment and α-synuclein expression leading to Parkinsonism. 31732923 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE PD is characterized by intraneuronal accumulation of abnormal α-synuclein in brainstem while neurodegenerative parkinsonisms might be associated with accumulation of either α-synuclein, as in the case of Multiple System Atrophy (MSA) or tau, as in the case of Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP), in other disease-specific brain regions. 31406572 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE Parkinsonism-linked mutations in alanine and glutamic acid residues of the pre-synaptic protein α-Synuclein (α-Syn) affect specific tertiary interactions essential for stability of the native state and make it prone to more aggregation. 31385584 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE We used a novel real-time quaking-induced conversion (RT-QuIC) assay to detect α-synuclein (α-syn) aggregates in cerebrospinal fluid (CSF) of 118 patients with parkinsonism of uncertain clinical etiology and 52 controls. 30801759 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders. 30706414 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. 30619023 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE Six α-synuclein (aSyn) point mutations are currently known to be associated with familial parkinsonism: A30P, E46K, H50Q, G51D, A53E, and A53T. 30605594 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE The operational definition requires clinical ascertainment of a levodopa-responsive parkinsonism with no "atypical" features, and pathological criteria based on the finding, usually at postmortem, of aggregates of α-synuclein in Lewy bodies and Lewy neurites. 30584155 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. 30423204 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE The aggregation of NFTs, the abnormal hyperphosphorylation of tau protein, and the interaction between tau and alpha-synuclein may all contribute to the cell death and poor axonal transport observed in PD and Parkinsonism. 30333786 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease. 30113007 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 AlteredExpression group BEFREE <b>Results:</b> Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (<i>p</i> < 0.01). 29755341 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE These data suggest that phosphorylated α-synuclein accumulates in the retina in parallel with that in the brain, including in early stages preceding development of clinical signs of parkinsonism or dementia. 29737566 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE It is now well established that LB-type α-synuclein aggregates also occur in the peripheral autonomic nervous system in PD, from where it has been speculated they may progressively spread to the central nervous system through synaptically-connected brain networks and reach the substantia nigra to trigger herein dopaminergic dysfunction/degeneration and subsequent parkinsonism. 29422109 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. 29310663 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE We performed Sanger sequencing of all coding LRRK2 and SNCA exons in a sample of 91 patients with Parkinsonism. 29248340 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE We screened for the p. A53T SNCA mutation a total of 347 cases of Greek origin with parkinsonism and/or dementia, collected over 15 years at the Neurogenetics Unit, Eginition Hospital, University of Athens. 29233723 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE The current study investigated the role of α-synuclein aggregation and UPS in Zn-induced Parkinsonism. 29198021 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3). 29124790 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. 29111028 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE We used two different procedures, first, the adoptive transfer of splenocytes from αSyn/Grp94-immunized mice to recipient animals, and second, direct immunization with αSyn/Grp94, to study the effects in a chronic mouse MPTP-model of parkinsonism. 29024008 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 AlteredExpression group BEFREE Our study is the first to uncover the potential link between manganese exposure, altered miRNA expression and parkinsonism: manganese exposure causes overexpression of SNCA and FGF-20 by diminishing miR-7 and miR-433 levels. 28986288 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE Synucleinopathies are a spectrum of neurodegenerative diseases characterized by the intracellular deposition of the protein α-synuclein leading to multiple outcomes, including dementia and Parkinsonism. 28910367 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 Biomarker group BEFREE We included studies that reported data on CSF total, oligomeric and phosphorylated α-synuclein in patients with PD and healthy participants, neurological controls, or other parkinsonisms. 28880418 2017
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.500 GeneticVariation group BEFREE For this study, SIRT3-myc was administered both before and after viral induction of parkinsonism with the AAV-expressing mutant (A53T) α-synuclein. 28673739 2017